- 发布时间：2020-12-30 11:38:22
In pursuit of providing patients with more suitable, more efficient and safer medicines, the company has carried out a wide range of diversified cooperation projects with the top international research institutions of tropical disease.
(1) Oxford University Tropical Medicine Research Units -- Mahidol Oxford Tropical Medicine Research Unit (MORU) : Partnership with the company since 2004. The two sides have conducted various international standarded clinical trials of more than 4000 cases, in regions with the highest incidence of malaria in the world, such as Africa and Southeast Asia. In order to continuously verify the efficacy of our medicines, and also to prove a good cure rate for human body in different races and individuals.
(2) World Health Organization Prequalificatin (WHO PQ) : The company pursues the goal of "providing the most effective medicines to the international market with the highest quality standards". After several rounds of discussions with the WHO expert group, and continuous improvement of the quality system, the company's API factory and formulation factory have passed the WHO GMP inspect, and the quality standards are in line with international standards. The main product "DUO-COTECXIN" is under the WHO pre-certification review, aiming to provide more safe and efficient antimalarial medicines to a wider range of the international community.
(3) National clinical research institutions in tropical areas: The company has registered its products in 39 countries around the world, and has carried out in-depth cooperation with tropical disease research institutes under the Ministry of Health of Kenya, Tanzania, Uganda, Senegal, Ghana, Thailand, Indonesia and Myanmar, as well as well-known universities. The main projects include participating in the formulation of local malaria medicines policy, implementing efficacy and comparative clinical trials, and implementing prospective clinical projects for new indication development.